1. Anti-infection
  2. Bacterial
  3. Dusquetide TFA

Dusquetide TFA (Synonyms: SGX942 TFA)

Cat. No.: HY-P2076A Purity: 98.49%
Handling Instructions

Dusquetide (SGX942) TFA is a first-in-class innate defense regulator (IDR). Dusquetide TFA modulates the innate immune response to both PAMPs and DAMPs by binding to p62. Dusquetide TFA shows activity in both reducing inflammation and increasing clearance of bacterial infection. DAMPs: damage-associated molecular patterns; PAMPs: pathogen-associated molecular patterns

For research use only. We do not sell to patients.

Dusquetide TFA Chemical Structure

Dusquetide TFA Chemical Structure

Size Price Stock Quantity
1 mg USD 220 In-stock
Estimated Time of Arrival: December 31
5 mg USD 560 In-stock
Estimated Time of Arrival: December 31
10 mg USD 950 In-stock
Estimated Time of Arrival: December 31
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Dusquetide TFA:

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Dusquetide (SGX942) TFA is a first-in-class innate defense regulator (IDR). Dusquetide TFA modulates the innate immune response to both PAMPs and DAMPs by binding to p62. Dusquetide TFA shows activity in both reducing inflammation and increasing clearance of bacterial infection[1]. DAMPs: damage-associated molecular patterns; PAMPs: pathogen-associated molecular patterns

In Vivo

Dusquetide (SGX942) TFA (25 mg/kg; i.v.; days 0, 4, 7, 10, and 14) shows no increase in tumor growth or worsening of survival and a trend towards decreased tumor growth and improvement in survival with radiation[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female nude mice (MCF-7 tumor xenografts)[1]
Dosage: 25 mg/kg
Administration: I.v.; days 0, 4, 7, 10, and 14
Result: Showed no increase in tumor growth or worsening of survival and a trend towards decreased tumor growth and improvement in survival with radiation.
Clinical Trial
Molecular Weight

667.72

Formula

C₂₇H₄₈F₃N₉O₇

Sequence

{Arg}{Ile}{Val}{Pro}{Ala}-NH2

Sequence Shortening

RIVPA-NH2

SMILES

C[[email protected]@H](C(N)=O)NC([[email protected]]1N(C([[email protected]](C(C)C)NC([[email protected]]([[email protected]@H](C)CC)NC([[email protected]](CCCNC(N)=N)N)=O)=O)=O)CCC1)=O.OC(C(F)(F)F)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage
Powder -80°C 2 years
-20°C 1 year
In solvent -80°C 6 months
-20°C 1 month
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Keywords:

DusquetideSGX942SGX 942SGX-942BacterialoralmucositisinnatedefenseregulatorimmunesystemheadneckcancerbreastInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email address *

Phone number *

 

Organization name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Dusquetide TFA
Cat. No.:
HY-P2076A
Quantity:
MCE Japan Authorized Agent: